Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics

Drug Profile

Research programme: astrocyte-derived neurotrophic factors - MANF Therapeutics

Alternative Names: AMRS-001; CDNF - MANF Therapeutics; Conserved dopaminergic neurotrophic factor; MANF; MANF-based therapeutics - MANF Therapeutics; Mesencephalic astrocyte-derived neurotrophic factor

Latest Information Update: 05 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amarantus Therapeutics; University of Miami
  • Developer Amarantus Bioscience Holdings; Generex Biotechnology Corporation; MANF Therapeutics
  • Class Antidementias; Antiparkinsonians; Cardiovascular therapies; Eye disorder therapies; Nerve growth factors; Recombinant proteins
  • Mechanism of Action Apoprotein inhibitors; Apoptosis inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa; Retinal vein occlusion
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetes mellitus; Glaucoma; Macular degeneration; Parkinson's disease; Retinal vein occlusion; Retinitis pigmentosa; Spinocerebellar degeneration; Stroke
  • Research Alzheimer's disease
  • No development reported Amyotrophic lateral sclerosis; Brain injuries; Ischaemic heart disorders

Most Recent Events

  • 17 Nov 2017 Astrocyte-derived neurotrophic factors are still undergoing preclinical development for Retinitis pigmentosa, Parkinson's disease and Diabetes mellitus in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Retinitis-pigmentosa in USA (Intravitreous, Injection)
  • 17 Apr 2017 Amarantus Biosciences Holdings formed its subsidiary named MANF Therapeutics, that will be focusing on the development of MANF-based protein therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top